IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Tom - another brilliant link. But you need to re-read the RNS. It wasn't a placeholding statement while they get their ducks in a row and continue the big plan. It was a capitulation. Financial and scientific capitulation and surrender. An admission that the SNG (with Synairgen) story is mostly over, and that if it wasn't, they don't have the cash to explore the last remaining tiny hope of salvation.
Keep up the good work though and please send anything you find to PO Box 25. Beckenham. Kent. BR3 4BR. Michelle will print it off and make paper airplanes
Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19
https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04388-8
The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). The use of intravenous Interferon beta (IFN β) for the treatment of ARDS was recently tested in a phase III ARDS trial
Could really do with his science knowledge
LMAO
Yes exactly Tommy (refering to the paper you posted), there is not much of a case for sng001 to be used in ards, or patients on respirators for that matter.
Mdpi is a predatory publisher (pretty much they'll publish anything the authors are willing to pay for). So saddly the article is irrelevant.
Lol lol lol . The Bird Flu story is back for our Pmj lol lol
Great to see BARDA moving into gear:
Moderna Gets $176 Million From the U.S. to Make a Bird Flu Vaccine
https://www.barrons.com/articles/moderna-stock-bird-flu-vaccine-82c0c41b
My thoughts on the delay Bob is that
As someone else suggested - they are close to being ready with an update on the Ventilated patient trial (on the verge) and maybe wanted to get it out with the results and B4 the AGM. It doesn't explain the missed AGM deadline but I can't think of anything else positive that might explain it. I'm disinclined to believe any of the tea leaf readers who have never once been right in any of their secret squirrel predictions. We know that when it looks like nothing is happening with this company - there really is nothing going on.
Appreciate your posts always of course
Hahaha !
MrCosts Thanks. I also noted at least some of the points you pointed too. We will know pretty soon just what the incredible delay is due too.
Doc.Daneeka You may well be right but I did use to be a very canny FD of big businesses and I am putting my money where my mouth is. What are your thoughts on the incredible delay in calling the AGM...positve (like me) or negative (reason) or you don't have an opinion?
It is now MrCosts working in haste ... to ramp the sp.
Sarcasm, MrCosts? I can't tell anymore.
Bob, I actually agree with everything you say.
This may surprise a few people, the RNS actually contains some hidden messages in view:
- Recognised that opportunities for potential future assessment of SNG001 in platform trials may materialise in the event of an emerging virus threat
- ...we are open for inclusion of SNG001 in platforms trials...
- ...we have regained momentum and stand on the verge
- ...remain open to other collaborations and platform trials in the future
- ...SNG001 continues to be an attractive asset for inclusion in platform trials, a position the company was not in prior to the pandemic
- I look forward to updating the market with great details on our development plans
Very exciting to be fair. Lots will happen between now and end of year.
-
"The recent BARDA announcement re. the PT for ARDS was released 24 June and SNG AR & Update followed on 27 June…very close timing. “An additional company and product may be added to the clinical trial at a later time. “ I do expect this to be SNG and that the hold up is due to the PU.RDAH caused by the unexpected election and that NHIR are planning a financed collaboration with SNG and BARDA Thanks again Brand. "
We all feel the same pain Bob, but Scotsmen are normally praised for their hardnosed cannyness, and if you really believe this you must have been dropped on your head as a baby. Raking through the ashes for comfort is one thing but the idea that Barda & NIH have been planning a big swoop for SNG - which is now on hold because of the election is just comical. And if it was somehow true then the results RNS was a really big lie.
We are waiting to hear more - to find out how far along the road they are with the ventilated patients trial - which SS told us they were "on the verge" of announcing. And we wait to hear how they hope to finance it. That's all there is.
Clearly, something is up…and I believe good news is imminent (I have topped up to 470k shares, unfortunately most are pre 21 Feb22.
At the last AGM, which I attended, Simon Shaw absolutely committed to improved investor communications…this has not happened, at all. I expect this to be necessitated by ongoing commercially sensitive discussions as I read him as an honourable person in both the meeting and offline discussion.
The recent BARDA announcement re. the PT for ARDS was released 24 June and SNG AR & Update followed on 27 June…very close timing. “An additional company and product may be added to the clinical trial at a later time. “ I do expect this to be SNG and that the hold up is due to the PURDAH caused by the unexpected election and that NHIR are planning a financed collaboration with SNG and BARDA. Thanks again Brand.
It appears to me that SNG have, in the past, communicated on presentations etc. However, I have not seen anything from them re. the presentation in Edinburgh or the re-testing by Porton Down…Why!
The BOD failing to call a timely AGM is incredible…unless some scenario as above is the reason.
I expect a favourable RNS on Friday or early next week including calling the AGM. Like all LTI’s, I have been disappointed\let down by SNG management on too many occasions, but I will stick my Scottish neck out and predict a different outcome (at least in the short term).
GLA
You could spend all day discussing this - or read Jonnyboy's reply.
" Funny enough I was looking at this. I see a trend of the accounts being posted near or around July 6th. So let’s see "
Thank you wpa5. What I meant by it not meaning anything is the same thing occurred last year without consequence. I think they are just slightly late again.
The links you have provided are still of interest, so thank you for sharing.
Interesting situation we/SNG find ourselves/themselves in.
Lots of questions without answers I'm afraid - so I post for others like me who may not be aware ..
Late filing is a ‘strict liability’ (criminal) offence so (defences aside) R v SNG Directors is already proven. Certainly, they are a long way (c. 12 mnths ?) from charges being laid, and £m’s in fines are paid every year for this so it’s fairly common. However, our respected Professor, Consultants, Doctors & Scientists are clearly not ones to play fast & loose with their life’s work, and would not want their good names tarnished, so what’s afoot?
“One of the significant tail risks for directors convicted of a late filing offence that it may have to be declared on foreign travel applications like the US ESTA or the EU equivalent, for years to come.”
“Further, for directors who are regulated professionals, their professional rules will, in many cases, require them to self-report the fact of the conviction. Clearly, that could have significant professional, financial and/or personal repercussions.”
Clearly there are defences e.g. “exceptional circumstances” & “outwith their control”, however, “… submitting these defences typically results in significant fact-gathering and presentation exercises.”
(Various online sources)
Who needs and aggravation or unwanted attention that brings, so what would be worth going down this long, but risky road?
Have the Co requested a filing extension ? if so why not listed as such on Co’s Hse for public/shareholder info?
Personally, I'm still hopeful and relatively positive, albeit from a position of general ignorance of the science, but belief in the concept and aim, so for me its pontificating about the silver lining behind this intriguing, if not threatening, cloud. GLA.
I recall the same 'Accounts overdue' notice was there last year. I don't think it means anything to be honest.
Here is the link for reference: https://find-and-update.company-information.service.gov.uk/company/05233429
Morning Brand!
Worth adding that Synairgen were featured in last July's UKRI Annual Report (P35): https://assets.publishing.service.gov.uk/media/64bf8a7fd4051a000d5a9242/ukri-annual-report-accounts-2022-2023-print-ready.pdf
Spinout develops faster diagnoses and alternative treatments for lung infections
Synairgen, a Southampton-based spinout company with 24 employees, is developing an inhaled interferon beta candidate for severe viral lung infections, including asthma, COPD and COVID-19. Engaging with Southampton General Hospital, Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow. Since its launch, Synairgen has raised more than £129 million to fund clinical trials, has increased its market capitalisation tenfold to £300 million, and has received £10 million through licensing. MRC-funded research has supported the discovery science underpinning inhaled interferon beta therapy for nearly five decades, identifying many of the disease mechanisms involved.
MRC is the Medical Research Council.
Furthermore, Synairgen are part of the UK Life Sciences Vision: https://www.gov.uk/government/publications/life-sciences-vision/life-sciences-vision-html published July 2021. The UK Life Sciences Vision is a strategic document that outlines the UK's plan to foster growth and innovation in the life sciences sector over the coming years. The vision aims to build on the strengths demonstrated during the COVID-19 pandemic, such as rapid vaccine development, to establish the UK as a global leader in life sciences.
One of the key components of the vision is:
Investment in Research and Development: It emphasises increased investment in R&D to drive innovation and maintain the UK's competitive edge. This includes supporting cutting-edge research and ensuring a pipeline of new treatments and technologies.
As always, something to store in the notes and keep an eye on.
PS: I was surprised that the company are set to announce a finance plan after previously informing investors that they had enough funds to run multiple small P2 trials. My initial assumption was a placing to fund the planned VP trial, but I cannot rule out the prospect of non-dilutive funding from the likes of the MRC, NIHR or even BARDA. I guess we will find out soon enough what the plan entails.
Funny enough I was looking at this. I see a trend of the accounts being posted near or around July 6th. So let’s see.
Your missing my updates! Not missing your sh#te!
So missing his important updates ?